European principles of inhibitor management in patients with haemophilia: implications of new treatment options

Hermans, Cédric;Giangrande, Paul L. F.;O’Mahony, Brian;de Kleijn, Piet;Lobet, Sébastien;et.al.
(2020) Orphanet Journal of Rare Diseases — Vol. 15, n° 1, p. 219 [1-4] (2020)

Files

2020_Hermans_Orphanet_J_Rare_Dis.pdf
  • Open Access
  • Adobe PDF
  • 483.32 KB
Download

Details

Authors
Show more
Abstract
(en) In light of the rapidly changing landscape of haemophilia treatment, the authors of the position paper on the “European Principles of Inhibitor Management” published in 2018 (Table 1) [1] now provide an update on the major impact of novel therapies that bypass and/or substitute clotting factor VIII (FVIII) and IX (FIX) in the care of haemophilia patients with FVIII- or FIX-neutralizing allo-inhibitory antibodies (inhibitors). [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Hermans, C., Giangrande, P. L. F., O’Mahony, B., de Kleijn, P., Bedford, M., Batorova, A., Blatný, J., & Jansone, K. (2020). European principles of inhibitor management in patients with haemophilia: implications of new treatment options. Orphanet Journal of Rare Diseases, 15(1), 219 [1-4]. https://doi.org/10.1186/s13023-020-01511-8 (Original work published 2020)